{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T12:14:38Z","timestamp":1793621678630,"version":"4.5.0"},"reference-count":118,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.gtc.2022.05.003","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T21:39:08Z","timestamp":1661809148000},"page":"649-666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"title":["Cancer in Inflammatory Bowel Disease"],"prefix":"10.1016","volume":"51","author":[{"given":"Adam S.","family":"Faye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariela K.","family":"Holmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan E.","family":"Axelrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gtc.2022.05.003_bib1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1146\/annurev-immunol-030409-101225","article-title":"Inflammatory bowel disease","volume":"28","author":"Kaser","year":"2010","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.gtc.2022.05.003_bib2","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2022.05.003_bib3","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: from 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2022.05.003_bib4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2022.05.003_bib5","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1053\/j.gastro.2005.12.035","article-title":"Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis","volume":"130","author":"Rutter","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2022.05.003_bib6","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1053\/j.gastro.2011.01.057","article-title":"Intestinal inflammation and cancer","volume":"140","author":"Ullman","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2022.05.003_bib7","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJMra1403718","article-title":"Cancers complicating inflammatory bowel disease","volume":"372","author":"Beaugerie","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2022.05.003_bib8","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/gut.48.4.526","article-title":"The risk of colorectal cancer in ulcerative colitis: a meta-analysis","volume":"48","author":"Eaden","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2022.05.003_bib9","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.3748\/wjg.v22.i20.4794","article-title":"Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment","volume":"22","author":"Axelrad","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gtc.2022.05.003_bib10","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z","article-title":"Cancer risk in patients with inflammatory bowel disease: a population-based study","volume":"91","author":"Bernstein","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.gtc.2022.05.003_bib11","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/MIB.0b013e31828029c0","article-title":"Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies","volume":"19","author":"Lutgens","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gtc.2022.05.003_bib12","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ajg.2015.65","article-title":"Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: An Updated Overview","volume":"110","author":"Choi","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2022.05.003_bib13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00384-017-2754-3","article-title":"A\u00a0meta-analysis of the clinicopathological characteristics and survival outcomes of inflammatory bowel disease associated colorectal cancer","volume":"32","author":"Reynolds","year":"2017","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.gtc.2022.05.003_bib14","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2022.05.003_bib15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.gastro.2003.11.010","article-title":"Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis","volume":"126","author":"Rutter","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2022.05.003_bib16","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/gutjnl-2017-314190","article-title":"Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study","volume":"68","author":"Choi","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2022.05.003_bib17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/MEG.0000000000000576","article-title":"Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies","volume":"28","author":"Zheng","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2022.05.003_bib18","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1053\/gast.2001.24052","article-title":"Family history as a risk factor for colorectal cancer in inflammatory bowel disease","volume":"120","author":"Askling","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2022.05.003_bib19","first-page":"12","article-title":"Cancer prevention in patients with inflammatory bowel disease","volume":"45","author":"Cleveland","year":"2021","journal-title":"Pract Gastroenterol"},{"key":"10.1016\/j.gtc.2022.05.003_bib20","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/ajg.2016.304","article-title":"Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study","volume":"111","author":"Cheddani","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2022.05.003_bib21","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s11605-010-1402-9","article-title":"Intestinal cancer risk in Crohn\u2019s disease: a meta-analysis","volume":"15","author":"Laukoetter","year":"2011","journal-title":"J\u00a0Gastrointest Surg"},{"key":"10.1016\/j.gtc.2022.05.003_bib22","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/j.cgh.2017.06.051","article-title":"Inflammatory Bowel Disease and Small Bowel Cancer Risk, Clinical Characteristics, and Histopathology: A Population-Based Study","volume":"15","author":"Bojesen","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2022.05.003_bib23","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1158\/1055-9965.EPI-10-1281","article-title":"Crohn\u2019s disease and small bowel adenocarcinoma: a population-based case-control study","volume":"20","author":"Shaukat","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.gtc.2022.05.003_bib24","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/01.mib.0000179211.03650.b6","article-title":"Small bowel adenocarcinoma in patients with Crohn\u2019s disease compared with small bowel adenocarcinoma de novo","volume":"11","author":"Palascak-Juif","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gtc.2022.05.003_bib25","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/BF01296557","article-title":"Risk factors for small bowel cancer in Crohn\u2019s disease","volume":"37","author":"Lashner","year":"1992","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gtc.2022.05.003_bib26","first-page":"205","article-title":"Risk factors for adenocarcinomas and malignant carcinoids of the small intestine: preliminary findings","volume":"3","author":"Chen","year":"1994","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.gtc.2022.05.003_bib27","doi-asserted-by":"crossref","first-page":"11486","DOI":"10.3748\/wjg.v20.i33.11486","article-title":"Small bowel adenocarcinoma and Crohn\u2019s disease: any further ahead than 50 years ago?","volume":"20","author":"Cahill","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.gtc.2022.05.003_bib28","first-page":"297","article-title":"Inflammatory bowel disease and risk of small bowel cancer: a binational population-based cohort study from Denmark and Sweden","volume":"70","author":"Axelrad","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2022.05.003_bib29","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41395-018-0360-9","article-title":"Malignancies in Inflammatory Bowel Disease: Frequency, Incidence and Risk Factors-Results from the Swiss IBD Cohort Study","volume":"114","author":"Scharl","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2022.05.003_bib30","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1002\/ibd.22889","article-title":"Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease","volume":"18","author":"Sokol","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gtc.2022.05.003_bib31","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1038\/ctg.2016.8","article-title":"Anal neoplasia in inflammatory bowel disease is associated with HPV and perianal disease","volume":"7","author":"Ruel","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.gtc.2022.05.003_bib32","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.cgh.2017.11.041","article-title":"High Risk of Anal and Rectal Cancer in Patients With Anal and\/or Perianal Crohn\u2019s Disease","volume":"16","author":"Beaugerie","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2022.05.003_bib33","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10654-009-9365-4","article-title":"Incidence and prognosis of cholangiocarcinoma in Danish patients with and without inflammatory bowel disease: a national cohort study, 1978-2003","volume":"24","author":"Erichsen","year":"2009","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.gtc.2022.05.003_bib34","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.cgh.2013.02.016","article-title":"Primary sclerosing cholangitis: diagnosis, prognosis, and management","volume":"11","author":"Singh","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2022.05.003_bib35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1572-0241.2004.04067.x","article-title":"Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis","volume":"99","author":"Burak","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2022.05.003_bib36","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","article-title":"Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012","volume":"151","author":"Rogers","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.gtc.2022.05.003_bib37","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2022.05.003_bib38","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.14309\/ajg.0000000000000679","article-title":"Repeated occurrences of basal cell cancer in patients with inflammatory bowel disease treated with immunosuppressive medications","volume":"115","author":"Khan","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2022.05.003_bib39","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1053\/j.gastro.2011.06.050","article-title":"Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease","volume":"141","author":"Peyrin-Biroulet","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2022.05.003_bib40","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1001\/jama.2014.5613","article-title":"Association between tumor necrosis factor-\u03b1 antagonists and risk of cancer in patients with inflammatory bowel disease","volume":"311","author":"Nyboe Andersen","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.gtc.2022.05.003_bib41","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamadermatol.2020.1300","article-title":"Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis","volume":"156","author":"Esse","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.gtc.2022.05.003_bib42","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cgh.2013.04.033","article-title":"Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis","volume":"12","author":"Singh","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2022.05.003_bib43","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cgh.2014.05.015","article-title":"Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis","volume":"13","author":"Kotlyar","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2022.05.003_bib44","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cgh.2010.09.016","article-title":"A\u00a0systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease","volume":"9","author":"Kotlyar","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2022.05.003_bib45","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.gtc.2022.05.003_bib46","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ecco-jcc\/jjy096","article-title":"Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Anti-tumour Necrosis Factor Alpha Agents: A Systematic Review and Meta-analysis","volume":"12","author":"Yang","year":"2018","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.gtc.2022.05.003_bib47","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2147\/CEG.S237646","article-title":"Risk of Lymphoma Associated with Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: Implications for Therapy","volume":"13","author":"Dahmus","year":"2020","journal-title":"Clin Exp Gastroenterol"},{"key":"10.1016\/j.gtc.2022.05.003_bib48","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/j.gastro.2013.12.025","article-title":"Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn\u2019s disease","volume":"146","author":"Osterman","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2022.05.003_bib49","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/apt.13466","article-title":"Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"43","author":"Bourrier","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2022.05.003_bib50","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/aje\/kws375","article-title":"Use of azathioprine and the risk of cancer in inflammatory bowel disease","volume":"177","author":"Pasternak","year":"2013","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.gtc.2022.05.003_bib51","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.eururo.2018.11.039","article-title":"Inflammatory bowel disease and the risk of prostate cancer","volume":"75","author":"Burns","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.gtc.2022.05.003_bib52","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1002\/ijc.33048","article-title":"Association between inflammatory bowel disease and prostate cancer: A large-scale, prospective, population-based study","volume":"147","author":"Meyers","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.gtc.2022.05.003_bib53","article-title":"Inflammatory bowel disease induces inflammatory and pre-neoplastic changes in the prostate","author":"Desai","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.gtc.2022.05.003_bib54","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cgh.2014.07.036","article-title":"Inflammatory bowel disease and cervical neoplasia: a population-based nationwide cohort study","volume":"13","author":"Rungoe","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2022.05.003_bib55","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/ecco-jcc\/jjab036","article-title":"Increased Risk of High-grade Cervical Neoplasia in Women with Inflammatory Bowel Disease: A Case-controlled Cohort Study","volume":"15","author":"Goetgebuer","year":"2021","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.gtc.2022.05.003_bib56","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1053\/j.gastro.2009.12.037","article-title":"AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease","volume":"138","author":"Farraye","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2022.05.003_bib57","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1136\/gut.2009.179804","article-title":"Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002)","volume":"59","author":"Cairns","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2022.05.003_bib58","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.crohns.2013.09.016","article-title":"European evidence based consensus for endoscopy in inflammatory bowel disease","volume":"7","author":"Annese","year":"2013","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.gtc.2022.05.003_bib59","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ajg.2009.727","article-title":"Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee","volume":"105","author":"Kornbluth","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2022.05.003_bib60","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.gie.2014.10.030","article-title":"The role of endoscopy in inflammatory bowel disease","volume":"81","author":"American Society for Gastrointestinal Endoscopy Standards of Practice Committee","year":"2015","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gtc.2022.05.003_bib61","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1038\/sj.bjc.6605359","article-title":"Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease","volume":"101","author":"Lutgens","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.gtc.2022.05.003_bib62","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/0016-5085(93)90715-O","article-title":"Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis","volume":"105","author":"Choi","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2022.05.003_bib63","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1053\/j.gastro.2021.05.063","article-title":"AGA clinical practice update on endoscopic surveillance and management of colorectal dysplasia in inflammatory bowel diseases: expert review","volume":"161","author":"Murthy","year":"2021","journal-title":"Gastroenterology"},{"issue":"Suppl 5","key":"10.1016\/j.gtc.2022.05.003_bib64","doi-asserted-by":"crossref","first-page":"V10","DOI":"10.1136\/gut.51.suppl_5.v10","article-title":"Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease","volume":"51","author":"Eaden","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2022.05.003_bib65","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1093\/ecco-jcc\/jjx105","article-title":"Corrigendum: Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management","volume":"11","author":"Harbord","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.gtc.2022.05.003_bib66","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.gie.2014.12.009","article-title":"SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease","volume":"81","author":"Laine","year":"2015","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gtc.2022.05.003_bib67","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/ecco-jcc\/jjv141","article-title":"European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies","volume":"9","author":"Annese","year":"2015","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.gtc.2022.05.003_bib68","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s10350-003-0049-y","article-title":"Surveillance for dysplasia in patients with inflammatory bowel disease: a national survey of colonoscopic practice in New Zealand","volume":"47","author":"Gearry","year":"2004","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.gtc.2022.05.003_bib69","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/ibd.20204","article-title":"Population-based analysis of practices and costs of surveillance for colonic dysplasia in patients with primary sclerosing cholangitis and colitis","volume":"13","author":"Kaplan","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gtc.2022.05.003_bib70","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0016-5107(00)70405-6","article-title":"How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance","volume":"51","author":"Eaden","year":"2000","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gtc.2022.05.003_bib71","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3748\/wjg.15.226","article-title":"Adherence to surveillance guidelines for dysplasia and colorectal carcinoma in ulcerative and Crohn\u2019s colitis patients in the Netherlands","volume":"15","author":"Rijn","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gtc.2022.05.003_bib72","first-page":"161","article-title":"Clinical implications of low grade dysplasia found during inflammatory bowel disease surveillance: a retrospective study comparing chromoendoscopy and white-light endoscopy","volume":"49","author":"Ten Hove","year":"2017","journal-title":"Endoscopy"},{"key":"10.1016\/j.gtc.2022.05.003_bib73","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/gutjnl-2016-311892","article-title":"Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy?","volume":"67","author":"Moussata","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2022.05.003_bib74","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1053\/j.gastro.2017.11.224","article-title":"P172 chromoendoscopy versus high definition white light endoscopy for dysplasia detection in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"154","author":"Jegadeesan","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2022.05.003_bib75","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.14309\/ajg.0000000000000341","article-title":"High-Definition Chromoendoscopy Versus High-Definition White Light Colonoscopy for Neoplasia Surveillance in Ulcerative Colitis: A Randomized Controlled Trial","volume":"114","author":"Yang","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2022.05.003_bib76","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1055\/s-2007-966214","article-title":"Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis","volume":"39","author":"Dekker","year":"2007","journal-title":"Endoscopy"},{"key":"10.1016\/j.gtc.2022.05.003_bib77","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.gie.2011.05.013","article-title":"Narrow-band imaging as an alternative to chromoendoscopy for the detection of dysplasia in long-standing inflammatory bowel disease: a prospective, randomized, crossover study","volume":"74","author":"Pellis\u00e9","year":"2011","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gtc.2022.05.003_bib78","doi-asserted-by":"crossref","first-page":"A221","DOI":"10.1136\/gut.2011.239301.467","article-title":"Outcome of benign strictures in ulcerative colitis","volume":"60","author":"Ignjatovic","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2022.05.003_bib79","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ajg.2017.417","article-title":"A\u00a0randomized trial comparing high definition colonoscopy alone with high definition dye spraying and electronic virtual chromoendoscopy for detection of colonic neoplastic lesions during IBD surveillance colonoscopy","volume":"113","author":"Iacucci","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2022.05.003_bib80","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/ibd\/izaa011","article-title":"Meta-analysis of Virtual-based Chromoendoscopy Compared With Dye-spraying Chromoendoscopy Standard and High-definition White Light Endoscopy in Patients With Inflammatory Bowel Disease at Increased Risk of Colon Cancer","volume":"26","author":"El-Dallal","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gtc.2022.05.003_bib81","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.cgh.2016.11.021","article-title":"Chromoendoscopy for surveillance in ulcerative colitis and Crohn\u2019s disease: A systematic review of randomized trials","volume":"15","author":"Iannone","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2022.05.003_bib82","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2022.05.003_bib83","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/ajg.2011.93","article-title":"Random biopsies taken during colonoscopic surveillance of patients with longstanding ulcerative colitis: low yield and absence of clinical consequences","volume":"109","author":"van den Broek","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2022.05.003_bib84","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.gie.2006.09.025","article-title":"Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis?","volume":"65","author":"Rubin","year":"2007","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gtc.2022.05.003_bib85","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0016-5107(03)02159-X","article-title":"The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002","volume":"58","author":"Anon","year":"2003","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gtc.2022.05.003_bib86","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1055\/s-2005-861352","article-title":"Update on the Paris classification of superficial neoplastic lesions in the digestive tract","volume":"37","year":"2005","journal-title":"Endoscopy"},{"key":"10.1016\/j.gtc.2022.05.003_bib87","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.cgh.2013.07.024","article-title":"Cancer risk after resection of polypoid dysplasia in patients with longstanding ulcerative colitis: a meta-analysis","volume":"12","author":"Wanders","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2022.05.003_bib88","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/ajg.2013.126","article-title":"Tracking the molecular features of nonpolypoid colorectal neoplasms: a systematic review and meta-analysis","volume":"108","author":"Voorham","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2022.05.003_bib89","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1002\/ibd.21184","article-title":"Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis","volume":"16","author":"Pekow","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gtc.2022.05.003_bib90","doi-asserted-by":"crossref","first-page":"e684","DOI":"10.1016\/j.crohns.2013.06.006","article-title":"Progression of low-grade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance","volume":"7","author":"Navaneethan","year":"2013","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.gtc.2022.05.003_bib91","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/ibd.22912","article-title":"Prospective study of the progression of low-grade dysplasia in ulcerative colitis using current cancer surveillance guidelines","volume":"18","author":"Zisman","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gtc.2022.05.003_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gie.2015.03.1967","article-title":"The role of endoscopy in the management of premalignant and malignant conditions of the stomach","volume":"82","author":"ASGE Standards of Practice Committee","year":"2015","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gtc.2022.05.003_bib93","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ajg.2015.248","article-title":"Low-grade dysplasia in ulcerative colitis: risk factors for developing high-grade dysplasia or colorectal cancer","volume":"110","author":"Choi","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2022.05.003_bib94","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.gie.2015.02.052","article-title":"Curative endoscopic submucosal dissection of large nonpolypoid superficial neoplasms in ulcerative colitis (with videos)","volume":"82","author":"Iacopini","year":"2015","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gtc.2022.05.003_bib95","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1055\/s-0043-114410","article-title":"Endoscopic submucosal dissection of colitis-related dysplasia","volume":"49","author":"Suzuki","year":"2017","journal-title":"Endoscopy"},{"key":"10.1016\/j.gtc.2022.05.003_bib96","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.gie.2017.10.035","article-title":"The role of colorectal endoscopic submucosal dissection in patients with ulcerative colitis","volume":"87","author":"Kinoshita","year":"2018","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gtc.2022.05.003_bib97","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/01.MIB.0000160811.76729.d5","article-title":"Crohn\u2019s and Colitis Foundation of America Colon Cancer in IBD Study Group. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease","volume":"11","author":"Itzkowitz","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gtc.2022.05.003_bib98","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/ibd\/izab039","article-title":"Aging and IBD: A new challenge for clinicians and researchers","volume":"28","author":"Faye","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gtc.2022.05.003_bib99","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.cgh.2012.06.016","article-title":"Effects of cancer treatment on inflammatory bowel disease remission and reactivation","volume":"10","author":"Axelrad","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2022.05.003_bib100","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.cgh.2019.06.042","article-title":"Hormone therapy for cancer is a risk factor for relapse of inflammatory bowel diseases","volume":"18","author":"Axelrad","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2022.05.003_bib101","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1572-0241.2007.01700.x","article-title":"Hormonal replacement therapy after menopause is protective of disease activity in women with inflammatory bowel disease","volume":"103","author":"Kane","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2022.05.003_bib102","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1111\/j.1572-0241.2008.02064.x","article-title":"The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis","volume":"103","author":"Cornish","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2022.05.003_bib103","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/s41395-018-0098-4","article-title":"Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn\u2019s Disease With up to 6 Years of Follow-Up in the Pyramid Registry","volume":"113","author":"D\u02bcHaens","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2022.05.003_bib104","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2022.05.003_bib105","doi-asserted-by":"crossref","first-page":"S316","DOI":"10.14309\/01.ajg.0000776320.54747.c3","article-title":"S697 Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease with Active or Recent Malignancy: A Multi-Center Cohort Study","volume":"116","author":"Holmer","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2022.05.003_bib106","doi-asserted-by":"crossref","first-page":"202","DOI":"10.14309\/ajg.0000000000000497","article-title":"Checkpoint Inhibitor-Induced Colitis","volume":"115","author":"Bellaguarda","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2022.05.003_bib107","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.gtc.2022.05.003_bib108","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2217\/imt.15.87","article-title":"Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"7","author":"Abdel-Rahman","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.gtc.2022.05.003_bib109","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review","volume":"160","author":"Dougan","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2022.05.003_bib110","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40425-018-0412-0","article-title":"Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis","volume":"6","author":"Johnson","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.gtc.2022.05.003_bib111","doi-asserted-by":"crossref","first-page":"e003277","DOI":"10.1136\/jitc-2021-003277","article-title":"Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study","volume":"9","author":"Zou","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.gtc.2022.05.003_bib112","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/apt.16217","article-title":"Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases","volume":"53","author":"Meserve","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2022.05.003_bib113","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1080\/1744666X.2019.1646127","article-title":"Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases","volume":"15","author":"Holmer","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.gtc.2022.05.003_bib114","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cgh.2015.07.037","article-title":"Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents","volume":"14","author":"Axelrad","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2022.05.003_bib115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.gastro.2016.03.037","article-title":"Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis","volume":"151","author":"Shelton","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2022.05.003_bib116","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.cgh.2018.09.035","article-title":"Retrospective analysis of safety of vedolizumab in patients with inflammatory bowel diseases","volume":"17","author":"Meserve","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2022.05.003_bib117","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cgh.2020.10.007","article-title":"Vedolizumab or tumor necrosis factor antagonist use and risk of new or recurrent cancer in patients with inflammatory bowel disease with prior malignancy: A retrospective cohort study","volume":"20","author":"Vedamurthy","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2022.05.003_bib118","doi-asserted-by":"crossref","first-page":"S340","DOI":"10.1016\/S0016-5085(21)01535-3","article-title":"Fr514 the sapphire registry: safety of immunosuppression in a prospective cohort of inflammatory bowel disease patients with a history of cancer","volume":"160","author":"Axelrad","year":"2021","journal-title":"Gastroenterology"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855322000267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855322000267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:41:42Z","timestamp":1760179302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889855322000267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":118,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0889855322000267"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2022.05.003","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer in Inflammatory Bowel Disease","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gtc.2022.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}